Asprosin levels in women with and without the polycystic ovary syndrome: a systematic review and meta-analysis

References

• Greenhill C. Liver: asprosin – new hormone involved in hepatic glucose release. Nat Rev Endocrinol. 2016;12(6):1.
   PubMedGoogle Scholar
• Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165(3):566–11.
   PubMed Web of Science ®Google Scholar
• Al-Daghri NM, Alokeel RMI, Alamro A, et al. Serum asprosin levels are associated with obesity and insulin resistance in Arab adults. J King Saud University Science. 2022;34(1):101690.
   Web of Science ®Google Scholar
• Ugur K, Aydin S. Saliva and blood asprosin hormone concentration associated with obesity. Int J Endocrinol. 2019;2019:2521096.
   PubMed Web of Science ®Google Scholar
• Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23(12):1444–1453.
   PubMed Web of Science ®Google Scholar
• Wang M, Yin C, Wang L, et al. Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann Nutr Metab. 2019;75(4):205–212.
   PubMed Web of Science ®Google Scholar
• Maylem ERS, Spicer LJ, Batalha I, et al. Discovery of a possible role of asprosin in ovarian follicular function. J Mol Endocrinol. 2021;66(1):35–44.
   PubMed Web of Science ®Google Scholar
• Maylem ERS, Spicer LJ, Atabay EP, et al. A potential role of fibrillin-1 (FBN1) mRNA and asprosin in follicular development in water buffalo. Theriogenology. 2022;178:67–72.
   PubMed Web of Science ®Google Scholar
• Ollila MM, West S, Keinänen-Kiukaanniemi S, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of type 2 diabetes mellitus-a prospective, population-based cohort study. Hum Reprod. 2017;32(2):423–431.
   PubMed Web of Science ®Google Scholar
• Kakoly NS, Khomami MB, Joham AE, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update. 2018;24(4):455–467.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, PRISMA Group, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341. Erratum in: Int J Surg 2010;8:658.12.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS. The Androgen Excess and PCOS Society. Criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2): 456–488.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47.
   PubMed Web of Science ®Google Scholar
• Plot Digitizer (version 4.5), https://automeris.io/WebPlotDigitizer/.
   Google Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
   PubMedGoogle Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Hedges LV. Fitting categorical models to effect sizes from a series of experiments. J Educ Stat. 1982;7(2):119–137.
   Google Scholar
• Deeks JJ, Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group 2010. Chapter 10: Analysing data and undertaking meta-analyses https://training.cochrane.org/handbook/current/chapter-10. Accessibility verified July 2, 2022.
   Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Alan M, Gurlek B, Yilmaz A, et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2019;35(3):220–223.
   PubMed Web of Science ®Google Scholar
• Ameen MR, Sulaiman DM, Muho KH. Serum asprosin levels in women with polycystic ovary syndrome in Duhok city, Kurdistan region of Iraq. J Life Biosci Res . 2021;2(2):36–41.
   Google Scholar
• Chang CL, Huang SY, Hsu YC, et al. The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. Sci Rep. 2019;9(1):6447.
   PubMed Web of Science ®Google Scholar
• Deniz R, Yavuzkir S, Ugur K, et al. Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome. J Obstet Gynaecol. 2021;41(2):279–284.
   PubMedGoogle Scholar
• Guo Y, Gao Y, Liu J. Serum asprosin level in patients with polycystic ovary syndrome and the influencing factors. Chin J Diabetes. 2020;28(10):720–732.
   Google Scholar
• Jiang Y, Liu Y, Yu Z, et al. Serum asprosin level in different subtypes of polycystic ovary syndrome: a cross-sectional study. Rev Assoc Med Bras (1992). 2021;67(4):590–596.
   PubMed Web of Science ®Google Scholar
• Li X, Liao M, Shen R, et al. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators of Inflammation. 2018;2018:1–12.
   Web of Science ®Google Scholar
• Liu W, Tang S, Wei S, et al. Relationship between serum asprosin level and insulin resistance in polycystic ovary syndrome. Zhejiang Med J. 2021;43(11):1217–1220.
   Google Scholar
• Polycystic Ovary, Endocrinology Group and Guidelines Expert Group Chinese Medical Association Obstetrics and Gynecology branch Chinese Journal of Diagnosis and Treatment of Syndrome. 中华医学会妇产科学分会内分泌学组及指南专家组多囊卵巢 综合征中国诊疗指南 中华妇产科杂志. Chin J Obstet Gynecol. 2018;53(1):2–6.
   Google Scholar
• Lee T, Yun S, Jeong JH, et al. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol. 2019;486:96–104.
   PubMed Web of Science ®Google Scholar
• Luís C, Fernandes R, Soares R, et al. A state of the art review on the novel mediator asprosin in the metabolic syndrome. Porto Biomed J. 2020;5(6):e108.
   PubMedGoogle Scholar
• Wang Y, Qu H, Xiong X, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm. 2018;2018:9471583.
   PubMed Web of Science ®Google Scholar
• Mishra I, Duerrschmid C, Ku Z, et al. Asprosin-neutralizing antibodies as a treatment for metabolic syndrome. Elife. 2021;10:e63784.
   PubMed Web of Science ®Google Scholar
• Ahmadabadi F, Nakhaei H, Mogharnasi M, et al. Aerobic interval training improves irisin and chemerin levels of both liver and visceral adipose tissues and circulating asprosin in rats with metabolic syndrome. Physiol Int. 2021;108(3):383–397.
   PubMed Web of Science ®Google Scholar
• Kantorowicz M, Szymura J, Szygula Z, et al. Nordic walking at maximal fat oxidation intensity decreases circulating asprosin and visceral obesity in women with metabolic disorders. Front Physiol. 2021;12:726783.
   PubMed Web of Science ®Google Scholar
• Hoffmann JG, Xie W, Chopra AR. Energy regulation mechanism and therapeutic potential of asprosin. Diabetes. 2020;69(4):559–566.
   PubMed Web of Science ®Google Scholar
• Tan S, Hahn S, Benson S, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol. 2007;157(5):669–676.
   PubMed Web of Science ®Google Scholar
• Kiconco S, Tay CT, Rassie KL, et al. Natural history of polycystic ovary syndrome: a systematic review of cardiometabolic outcomes from longitudinal cohort studies. Clin Endocrinol (Oxf). 2022;96(4):475–498.
   PubMed Web of Science ®Google Scholar
• Alba AC, Alexander PE, Chang J, et al. High statistical heterogeneity is more frequent in meta-analysis of continuous than binary outcomes. J Clin Epidemiol. 2016;70:129–135.
   PubMed Web of Science ®Google Scholar
• Usinger L, Reimer C, Ibsen H, Cochrane Hypertension Group Fermented milk for hypertension. Cochrane Database Syst Rev. 2012;18(4):CD008118.
   PubMed Web of Science ®Google Scholar
• Calvo F, Karras BT, Phillips R, et al. Diagnoses, syndromes, and diseases: a knowledge representation problem. AMIA Annu Symp Proc. 2003;2003:802.
   PubMedGoogle Scholar
• Naderpoor N, Shorakae S, de Courten B, et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015;21(5):560–574. Erratum in: Hum Reprod Update. 2016 ;22(3):408-9.
   PubMed Web of Science ®Google Scholar